BioCentury
ARTICLE | Clinical News

Ardelyx falls on CKD trial miss

May 7, 2015 2:30 AM UTC

Ardelyx Inc. (NASDAQ:ARDX) lost $2.61 (24%) to $8.30 on Wednesday after its tenapanor ( AZD1722) missed the primary endpoint in a Phase IIa trial to treat chronic kidney disease (CKD) stage 3 in patients with Type II diabetes.

In the 154-patient trial, tenapanor did not significantly reduce urinary albumin/creatine ratio vs. placebo from baseline to week 12 (16% vs. 11%) . Ardelyx did not provide a p-value. ...